Naturland Holding ZrtBUD:NATURLAND 61 EV-to-EBIT is 24.00 as of Jul. 11, 2026, which is 4% above its 10-year median of 23.16. GuruFocus rates BUD:NATURLAND with a GF Score™ of 61/100 and a GF Value™ of Ft2,888.55 (Fairly Valued). The stock has 5 warning signs investors should review. Among 689 Drug Manufacturers companies, Naturland Holding Zrt ranks worse than 65.02% on this metric.
The historical rank and industry rank for Naturland Holding Zrt's EV-to-EBIT or its related term are showing as below:
BUD:NATURLAND'
s EV-to-EBIT Range Over the Past 10 Years
Min: 11.67 Med: 23.16 Max: 41.24
Current: 23.99
During the past 5 years, the highest EV-to-EBIT of Naturland Holding Zrt was 41.24. The lowest was 11.67. And the median was 23.16.
BUD:NATURLAND's EV-to-EBIT is ranked worse than 65.02% of 689
companies
in the Drug Manufacturers industry
Industry Median: 15.81
vs BUD:NATURLAND: 23.99
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Naturland Holding Zrt's Enterprise Value for the quarter that ended in Jun. 2025 was Ft34,937 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Naturland Holding Zrt's EBIT for the trailing twelve months (TTM) ended in Jun. 2025 was Ft1,571 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BUD:NATURLAND vs ZTS, UTHR, VTRS: EV-to-EBIT Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Naturland Holding Zrt's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Naturland Holding Zrt EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Naturland Holding Zrt's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Naturland Holding Zrt's EV-to-EBIT falls into.
Naturland Holding Zrt's current Enterprise Value is Ft37,701 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Naturland Holding Zrt's EBIT for the trailing twelve months (TTM) ended in Jun. 2025 was Ft1,571 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Naturland Holding Zrt (BUD:NATURLAND) has a EV-to-EBIT of 24.00 as of Jul. 11, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Naturland Holding Zrt and its competitors. This is near median its historical median of 23.16. Over the past decade, Naturland Holding Zrt's EV-to-EBIT has ranged from 11.67 to 41.24. According to the industry distribution chart, Naturland Holding Zrt ranks #448 out of 689 companies in the Drug Manufacturers industry, placing it in the top 65%.
Is Naturland Holding Zrt's EV-to-EBIT too high?
Naturland Holding Zrt's current EV-to-EBIT of 24.00 is near median its 10-year median of 23.16. Over the past 10 years, this metric has ranged from a low of 11.67 to a high of 41.24. The Drug Manufacturers industry median EV-to-EBIT is 15.81. Naturland Holding Zrt's value of 24.00 is 51.8% above this industry median. Based on the distribution chart, Naturland Holding Zrt ranks #448 out of 689 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Naturland Holding Zrt has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Naturland Holding Zrt's EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Naturland Holding Zrt ranks #448 out of 689 companies for EV-to-EBIT. This places Naturland Holding Zrt in the lower half of its industry. The industry median EV-to-EBIT is 15.81. Naturland Holding Zrt's value of 24.00 is 51.8% above this benchmark. Historically, Naturland Holding Zrt's own EV-to-EBIT has ranged from 11.67 to 41.24 over the past decade. While the company's 10-year median is 23.16 vs. the industry median of 15.81, Naturland Holding Zrt has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.81, based on 689 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Naturland Holding Zrt's current EV-to-EBIT of 24.00 is 51.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Naturland Holding Zrt and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Naturland Holding Zrt's current EV-to-EBIT is 24.00, which is near median its own 10-year median of 23.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Naturland Holding Zrt stock overvalued right now?
Based on GuruFocus' analysis, Naturland Holding Zrt (BUD:NATURLAND) is currently considered Fairly Valued. The stock's GF Value™ is Ft2,888.55, compared to a current price of Ft2,740.00 — trading 5.1% below its estimated fair value. The current EV-to-EBIT is 24.00, which is near median its 10-year median of 23.16 and 51.8% above the Drug Manufacturers industry median of 15.81. Naturland Holding Zrt's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Naturland Holding Zrt (BUD:NATURLAND), the current EV-to-EBIT is 24.00 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Naturland Holding Zrt (BUD:NATURLAND) Overvalued in 2026?
Based on GuruFocus' analysis, Naturland Holding Zrt stock appears to be undervalued.
The current stock price of Ft2,740.00 is trading 5.1% below its estimated GF Value™ of Ft2,888.55.
GuruFocus considers Naturland Holding Zrt to be Fairly Valued.
Key valuation signals for BUD:NATURLAND:
EV-to-EBIT: 24.00 (near median its 10-year median of 23.16)
GF Value™: Ft2,888.55 vs. price of Ft2,740.00 (5.1% below fair value)
Industry Position: 51.8% above the Drug Manufacturers median (#448 of 689)
No single metric tells the full story. See the BUD:NATURLAND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Naturland Holding Zrt thro9ugh its subsidiaries engage in the production of pharmaceutical products. It engages in the development, production, and wholesale of dietary supplements and cosmetics, herbal medicine, teas, and essential oils. The firm offers tablets, suppositories, ointments, and ophthalmic base solutions.
61GF Score
Get the complete analysis for BUD:NATURLAND
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BUD:NATURLAND has been successfully added to your 
